Jennifer McDevitt

552 total citations
22 papers, 338 citations indexed

About

Jennifer McDevitt is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Jennifer McDevitt has authored 22 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Jennifer McDevitt's work include Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jennifer McDevitt is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jennifer McDevitt collaborates with scholars based in United States, Ireland and South Korea. Jennifer McDevitt's co-authors include Crystal S. Denlinger, Patricia C. Ryan, Gabriel J. Robbie, Haifeng Bao, Michael J. Pishvaian, Song Ren, Michael A. Morse, Sattva S. Neelapu, Frederick L. Locke and Michael Tees and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jennifer McDevitt

21 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer McDevitt United States 9 207 126 105 64 42 22 338
Xingxing Qi China 9 259 1.3× 111 0.9× 165 1.6× 27 0.4× 50 1.2× 11 466
Lan Shi China 11 156 0.8× 145 1.2× 86 0.8× 28 0.4× 66 1.6× 27 463
Milim Kim South Korea 11 183 0.9× 94 0.7× 51 0.5× 77 1.2× 125 3.0× 26 386
Winifred Lo United States 8 289 1.4× 138 1.1× 181 1.7× 49 0.8× 64 1.5× 15 455
Brigida Anna Maiorano Italy 15 343 1.7× 125 1.0× 145 1.4× 24 0.4× 67 1.6× 58 531
Betsy Morrow United States 11 180 0.9× 122 1.0× 56 0.5× 18 0.3× 41 1.0× 18 497
Erica Marchlik United States 3 145 0.7× 101 0.8× 39 0.4× 10 0.2× 83 2.0× 7 295
Eggermont Am Netherlands 8 216 1.0× 108 0.9× 88 0.8× 15 0.2× 23 0.5× 12 317
Candy Garcia United States 3 393 1.9× 81 0.6× 207 2.0× 51 0.8× 16 0.4× 3 484
Guo‐He Lin China 10 266 1.3× 118 0.9× 103 1.0× 10 0.2× 82 2.0× 37 427

Countries citing papers authored by Jennifer McDevitt

Since Specialization
Citations

This map shows the geographic impact of Jennifer McDevitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer McDevitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer McDevitt more than expected).

Fields of papers citing papers by Jennifer McDevitt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer McDevitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer McDevitt. The network helps show where Jennifer McDevitt may publish in the future.

Co-authorship network of co-authors of Jennifer McDevitt

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer McDevitt. A scholar is included among the top collaborators of Jennifer McDevitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer McDevitt. Jennifer McDevitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Locke, Frederick L., Shahbaz A. Malik, Michael Tees, et al.. (2021). First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.. Journal of Clinical Oncology. 39(15_suppl). 2529–2529. 21 indexed citations
2.
Neelapu, Sattva S., Javier Muñoz, Frederick L. Locke, et al.. (2020). First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.. Journal of Clinical Oncology. 38(15_suppl). 8002–8002. 38 indexed citations
3.
Whiting, Chan C., Nicholas Stock, Davorka Messmer, et al.. (2019). Abstract 3606: Blockade of the PPARα metabolic checkpoint with TPST-1120 suppresses tumor growth and stimulates anti-tumor immunity. Cancer Research. 79(13_Supplement). 3606–3606. 1 indexed citations
4.
Hyman, David M., Naiyer A. Rizvi, Ronald B. Natale, et al.. (2018). Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clinical Cancer Research. 24(12). 2749–2757. 38 indexed citations
5.
6.
Hamid, Omid, Laura Q.M. Chow, Rachel E. Sanborn, et al.. (2016). Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies. Annals of Oncology. 27. vi360–vi360. 8 indexed citations
7.
Pishvaian, Michael J., Michael A. Morse, Jennifer McDevitt, et al.. (2016). Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas. Clinical Colorectal Cancer. 15(4). 345–351. 73 indexed citations
8.
Pishvaian, Michael J., Michael A. Morse, Jennifer McDevitt, et al.. (2016). Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen (CEA), in patients with advanced gastrointestinal (GI) adenocarcinomas.. Journal of Clinical Oncology. 34(4_suppl). 320–320. 5 indexed citations
9.
Leidner, Rom S., Sandip Pravin Patel, Matthew G. Fury, et al.. (2015). A phase I study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of MEDI0562 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology. 33(15_suppl). TPS6083–TPS6083. 4 indexed citations
10.
11.
Haluska, Paul, Michael E. Menefee, Elizabeth R. Plimack, et al.. (2014). Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(18). 4747–4757. 55 indexed citations
12.
Hyman, David M., Naiyer A. Rizvi, Ronald B. Natale, et al.. (2014). A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 3012–3012. 1 indexed citations
13.
Natale, Ronald B., Naiyer A. Rizvi, Jeffrey R. Infante, et al.. (2012). Safety, pharmacokinetics, and antitumor activity of MEDI3617, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). TPS2621–TPS2621. 8 indexed citations
14.
Menefee, Michael E., P. LoRusso, Jennifer McDevitt, et al.. (2010). 3LB MEDI-573, a dual IGF-1/-2 neutralizing antibody, blocks IGF-1R and IR-A signaling and maintains glucose homeostasis in a Phase 1 study for advanced solid tumors. European Journal of Cancer Supplements. 8(7). 3–4. 1 indexed citations
15.
Kreitman, R. J., Steven Coutré, Tadeusz Robak, et al.. (2010). Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia.. Journal of Clinical Oncology. 28(15_suppl). 6523–6523. 6 indexed citations
16.
Wayne, Alan S., Deepa Bhojwani, Kelly Richards, et al.. (2010). Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox. Blood. 116(21). 3246–3246. 7 indexed citations
17.
Wayne, Alan S., Deepa Bhojwani, Sima Jeha, et al.. (2009). Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).. Blood. 114(22). 839–839. 7 indexed citations
18.
Maxwell, W.M.C., et al.. (1993). Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.. PubMed. 19(3). 265–72. 8 indexed citations
19.
McDevitt, Jennifer, et al.. (1991). Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2α. British Journal of Cancer. 64(5). 915–918. 21 indexed citations
20.
Maroko, Peter R., Jennifer McDevitt, Michael Fox, et al.. (1989). Antihypertensive effectiveness of very low doses of hydrochlorothiazide: results of the PHICOG Trial.. PubMed. 11(1). 94–119. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xingxing Qi Breakdown of academic impact, for papers by Lan Shi Breakdown of academic impact, for papers by Milim Kim Breakdown of academic impact, for papers by Winifred Lo Breakdown of academic impact, for papers by Brigida Anna Maiorano Breakdown of academic impact, for papers by Betsy Morrow Breakdown of academic impact, for papers by Erica Marchlik Breakdown of academic impact, for papers by Eggermont Am Breakdown of academic impact, for papers by Candy Garcia Breakdown of academic impact, for papers by Guo‐He Lin
Rankless by CCL
2026